Published in Nat Rev Drug Discov on May 01, 2010
Molecular signatures of G-protein-coupled receptors. Nature (2013) 5.19
Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol (2011) 3.15
β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci (2011) 3.02
Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature (2012) 2.88
Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med (2010) 2.82
Activation mechanism of the β2-adrenergic receptor. Proc Natl Acad Sci U S A (2011) 2.53
Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS Comput Biol (2011) 2.31
Multiple ligand-specific conformations of the β2-adrenergic receptor. Nat Chem Biol (2011) 2.23
Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol (2011) 2.08
Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest (2013) 2.06
Effects of small platform catheter-based left ventricular assist device support on regional myocardial signal transduction. J Thorac Cardiovasc Surg (2015) 2.02
Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A (2011) 1.97
Nanobody stabilization of G protein-coupled receptor conformational states. Curr Opin Struct Biol (2011) 1.75
Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov (2012) 1.75
Structure-based drug screening for G-protein-coupled receptors. Trends Pharmacol Sci (2012) 1.72
Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist. Sci Signal (2013) 1.71
Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. Br J Pharmacol (2012) 1.69
The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer (2010) 1.62
Distinct profiles of functional discrimination among G proteins determine the actions of G protein-coupled receptors. Sci Signal (2015) 1.61
β-arrestin1-biased β1-adrenergic receptor signaling regulates microRNA processing. Circ Res (2013) 1.59
Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc Natl Acad Sci U S A (2012) 1.57
Crystal structures of a stabilized β1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure (2012) 1.55
The GPCR Network: a large-scale collaboration to determine human GPCR structure and function. Nat Rev Drug Discov (2012) 1.50
New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma. Br J Pharmacol (2011) 1.46
A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Sci Signal (2011) 1.45
The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res (2011) 1.44
Recent developments in biased agonism. Curr Opin Cell Biol (2013) 1.44
Selective repression of MEF2 activity by PKA-dependent proteolysis of HDAC4. J Cell Biol (2011) 1.42
Structural insights into adrenergic receptor function and pharmacology. Trends Pharmacol Sci (2011) 1.42
A new era of GPCR structural and chemical biology. Nat Chem Biol (2012) 1.41
The significance of G protein-coupled receptor crystallography for drug discovery. Pharmacol Rev (2011) 1.39
Ten questions about systems biology. J Physiol (2011) 1.36
Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood (2012) 1.35
G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat Rev Drug Discov (2012) 1.35
Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation. Nat Med (2011) 1.31
The circadian clock in cancer development and therapy. Prog Mol Biol Transl Sci (2013) 1.28
Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat Protoc (2011) 1.26
Structure-based systems biology for analyzing off-target binding. Curr Opin Struct Biol (2011) 1.25
G protein-coupled receptors: mutations and endocrine diseases. Nat Rev Endocrinol (2011) 1.23
Allosteric interactions across native adenosine-A3 receptor homodimers: quantification using single-cell ligand-binding kinetics. FASEB J (2011) 1.21
Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo. J Neurosci (2010) 1.21
Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through β-arrestin and dishevelled-2 scaffolds. Proc Natl Acad Sci U S A (2011) 1.16
Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor. Mol Pharmacol (2012) 1.16
GPCRs regulate the assembly of a multienzyme complex for purine biosynthesis. Nat Chem Biol (2011) 1.15
Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Mol Pharmacol (2011) 1.15
Topological and functional characterization of an insect gustatory receptor. PLoS One (2011) 1.15
Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr Opin Cell Biol (2014) 1.14
Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ (2013) 1.13
Ligand-directed signalling within the opioid receptor family. Br J Pharmacol (2012) 1.13
Β-arrestin: a signaling molecule and potential therapeutic target for heart failure. J Mol Cell Cardiol (2010) 1.11
Quantification of receptor tyrosine kinase transactivation through direct dimerization and surface density measurements in single cells. Proc Natl Acad Sci U S A (2011) 1.10
Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor. Oncogene (2011) 1.09
Recognition in the face of diversity: interactions of heterotrimeric G proteins and G protein-coupled receptor (GPCR) kinases with activated GPCRs. J Biol Chem (2011) 1.07
Modulating neuromodulation by receptor membrane traffic in the endocytic pathway. Neuron (2012) 1.07
A nanomolar-potency small molecule inhibitor of regulator of G-protein signaling proteins. Biochemistry (2011) 1.07
Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. J Transl Med (2012) 1.06
Targeting G protein coupled receptor-related pathways as emerging molecular therapies. Saudi Pharm J (2013) 1.06
The quest to understand heterotrimeric G protein signaling. Nat Struct Mol Biol (2010) 1.06
Modelling three-dimensional protein structures for applications in drug design. Drug Discov Today (2013) 1.05
Activated protein C: biased for translation. Blood (2015) 1.05
The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling. Nat Commun (2012) 1.05
The experimental power of FR900359 to study Gq-regulated biological processes. Nat Commun (2015) 1.04
Novel designer receptors to probe GPCR signaling and physiology. Trends Pharmacol Sci (2013) 1.03
Circulating Exosomes Induced by Cardiac Pressure Overload Contain Functional Angiotensin II Type 1 Receptors. Circulation (2015) 1.02
Neutrophil elastase and proteinase-3 trigger G protein-biased signaling through proteinase-activated receptor-1 (PAR1). J Biol Chem (2013) 1.02
Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev (2012) 1.01
Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptor. ACS Chem Biol (2013) 1.01
β-Arrestin 1 inhibits the GTPase-activating protein function of ARHGAP21, promoting activation of RhoA following angiotensin II type 1A receptor stimulation. Mol Cell Biol (2010) 1.01
Molecular and cellular analysis of human histamine receptor subtypes. Trends Pharmacol Sci (2012) 1.01
β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma. Proc Natl Acad Sci U S A (2012) 1.01
Erythrocyte plasma membrane-bound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium. Blood (2011) 1.00
Biased agonism as a mechanism for differential signaling by chemokine receptors. J Biol Chem (2013) 1.00
Developing chemical genetic approaches to explore G protein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL). Mol Pharmacol (2011) 1.00
The antidepressant desipramine is an arrestin-biased ligand at the α(2A)-adrenergic receptor driving receptor down-regulation in vitro and in vivo. J Biol Chem (2011) 1.00
Ligand bias at metabotropic glutamate 1a receptors: molecular determinants that distinguish β-arrestin-mediated from G protein-mediated signaling. Mol Pharmacol (2012) 1.00
Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor. Exp Diabetes Res (2012) 0.99
Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of protease-activated receptor 3. Blood (2013) 0.99
Functional selectivity in adrenergic and angiotensin signaling systems. Mol Pharmacol (2010) 0.99
Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes. J Biol Chem (2011) 0.98
D1 dopamine receptor coupling to PLCβ regulates forward locomotion in mice. J Neurosci (2013) 0.98
Protease-activated receptors and myocardial infarction. IUBMB Life (2011) 0.98
AKAP signaling complexes: pointing towards the next generation of therapeutic targets? Trends Pharmacol Sci (2013) 0.98
CXCL12 signaling in the development of the nervous system. J Neuroimmune Pharmacol (2012) 0.98
Drug discovery opportunities and challenges at g protein coupled receptors for long chain free Fatty acids. Front Endocrinol (Lausanne) (2012) 0.98
PTH receptor-1 signalling-mechanistic insights and therapeutic prospects. Nat Rev Endocrinol (2015) 0.98
Amyloid beta peptide-(1-42) induces internalization and degradation of beta2 adrenergic receptors in prefrontal cortical neurons. J Biol Chem (2011) 0.98
Expression and membrane topology of Anopheles gambiae odorant receptors in lepidopteran insect cells. PLoS One (2010) 0.97
GPCR expression in tissues and cells: are the optimal receptors being used as drug targets? Br J Pharmacol (2012) 0.97
New developments in C5a receptor signaling. Cell Health Cytoskelet (2012) 0.97
Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci (2011) 0.97
Ligand-specific endocytic dwell times control functional selectivity of the cannabinoid receptor 1. Nat Commun (2014) 0.95
Biased and constitutive signaling in the CC-chemokine receptor CCR5 by manipulating the interface between transmembrane helices 6 and 7. J Biol Chem (2013) 0.95
Functional selectivity of adenosine receptor ligands. Purinergic Signal (2011) 0.93
Where have all the active receptor states gone? Nat Chem Biol (2012) 0.93
Structure determination of membrane proteins by nuclear magnetic resonance spectroscopy. Annu Rev Anal Chem (Palo Alto Calif) (2013) 0.93
Ligand modulation of the Epstein-Barr virus-induced seven-transmembrane receptor EBI2: identification of a potent and efficacious inverse agonist. J Biol Chem (2011) 0.92
Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering. FASEB J (2013) 0.92
A biased ligand for OXE-R uncouples Gα and Gβγ signaling within a heterotrimer. Nat Chem Biol (2012) 0.92
Orexin/hypocretin receptor signalling cascades. Br J Pharmacol (2014) 0.92
Identification and profiling of novel α1A-adrenoceptor-CXC chemokine receptor 2 heteromer. J Biol Chem (2012) 0.92
Transduction of receptor signals by beta-arrestins. Science (2005) 9.87
Beta-arrestins and cell signaling. Annu Rev Physiol (2007) 8.65
Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science (1999) 7.57
Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature (1996) 6.32
Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov (2008) 6.18
A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem (1980) 6.06
An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell (2005) 5.60
beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem (2005) 4.91
Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci U S A (2001) 4.56
beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science (1990) 4.53
A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem (1993) 4.52
Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci (2004) 4.44
Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science (1996) 4.38
Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci (2007) 4.35
beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol (2000) 4.29
Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science (1999) 4.04
Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu Rev Pharmacol Toxicol (2008) 4.04
Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A (2003) 3.99
A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A (2007) 3.82
Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science (2002) 3.46
Phosphodiesterase activation by photoexcited rhodopsin is quenched when rhodopsin is phosphorylated and binds the intrinsic 48-kDa protein of rod outer segments. Proc Natl Acad Sci U S A (1986) 3.38
Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci (1995) 3.25
A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell (2005) 3.22
Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest (2007) 3.15
The genetic design of signaling cascades to record receptor activation. Proc Natl Acad Sci U S A (2007) 3.11
Beta-arrestin-mediated localization of smoothened to the primary cilium. Science (2008) 3.10
Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci U S A (2007) 3.08
Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem (2004) 3.07
Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem (2006) 3.00
Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol (1998) 2.94
Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nat Biotechnol (2003) 2.84
A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell (2008) 2.76
The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex. Proc Natl Acad Sci U S A (2000) 2.69
Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol (2006) 2.69
Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell (2007) 2.65
Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol (2009) 2.60
beta-arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem (2007) 2.51
The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem (2002) 2.47
beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. J Biol Chem (2002) 2.42
Light-dependent phosphorylation of rhodopsin: number of phosphorylation sites. Biochemistry (1982) 2.42
WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood (2004) 2.41
beta-arrestins: traffic cops of cell signaling. Curr Opin Cell Biol (2004) 2.40
Identification of beta-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways. Mol Cell (2004) 2.37
GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci (2007) 2.35
Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem (2004) 2.31
Deficiency of a beta-arrestin-2 signal complex contributes to insulin resistance. Nature (2009) 2.27
A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med (2009) 2.24
Beta-adrenergic receptor kinase: primary structure delineates a multigene family. Science (1989) 2.24
Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol Sci (2004) 2.22
Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci (2007) 2.13
Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci (2007) 2.10
A molecular pathway for light-dependent photoreceptor apoptosis in Drosophila. Neuron (2000) 2.10
Functional desensitization of the isolated beta-adrenergic receptor by the beta-adrenergic receptor kinase: potential role of an analog of the retinal protein arrestin (48-kDa protein). Proc Natl Acad Sci U S A (1987) 2.08
An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization. Mol Pharmacol (2006) 2.06
Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. Proc Natl Acad Sci U S A (2008) 2.06
Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci U S A (2006) 2.01
Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A (2006) 1.97
beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc Natl Acad Sci U S A (2004) 1.91
The formation of stable rhodopsin-arrestin complexes induces apoptosis and photoreceptor cell degeneration. Neuron (2000) 1.88
Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci U S A (2009) 1.84
Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol (2002) 1.84
Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther (2005) 1.79
beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest (2009) 1.79
Beta-arrestin1 mediates insulin-like growth factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and anti-apoptosis. J Biol Chem (2003) 1.76
beta-Arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J Biol Chem (2004) 1.75
Light-dependent phosphorylation of rhodopsin. Purification and properties of rhodopsin kinase. J Biol Chem (1978) 1.75
Catecholamine-induced desensitization of turkey erythrocyte adenylate cyclase is associated with phosphorylation of the beta-adrenergic receptor. Proc Natl Acad Sci U S A (1983) 1.74
Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity. J Biol Chem (1997) 1.70
Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A (2008) 1.67
Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol Pharmacol (2004) 1.67
CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. Blood (2008) 1.66
Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. EMBO Rep (2005) 1.65
A beta-arrestin-dependent scaffold is associated with prolonged MAPK activation in pseudopodia during protease-activated receptor-2-induced chemotaxis. J Biol Chem (2003) 1.64
Beta-arrestin signaling and regulation of transcription. J Cell Sci (2007) 1.62
Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C2 adrenergic receptors to Gi and Gs. J Biol Chem (1992) 1.62
Nuclear beta-arrestin1 functions as a scaffold for the dephosphorylation of STAT1 and moderates the antiviral activity of IFN-gamma. Mol Cell (2008) 1.62
Molecular basis of inverse agonism in a G protein-coupled receptor. Nat Chem Biol (2005) 1.60
Regulation of tyrosine kinase activation and granule release through beta-arrestin by CXCRI. Nat Immunol (2000) 1.60
{beta}-Arrestin-2 Mediates Anti-apoptotic Signaling through Regulation of BAD Phosphorylation. J Biol Chem (2009) 1.59
The cubic ternary complex receptor-occupancy model. III. resurrecting efficacy. J Theor Biol (1996) 1.59
Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A (2009) 1.59
Independent beta-arrestin2 and Gq/protein kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. J Biol Chem (2009) 1.57
Arrestins block G protein-coupled receptor-mediated apoptosis. J Biol Chem (2004) 1.53
Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci U S A (2008) 1.51
Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci (2008) 1.50
Beta-arrestin binding to the beta2-adrenergic receptor requires both receptor phosphorylation and receptor activation. J Biol Chem (2005) 1.50
Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci (2003) 1.49
The role of a conserved region of the second intracellular loop in AT1 angiotensin receptor activation and signaling. Endocrinology (2003) 1.49
Beta-arrestin is a necessary component of Wnt/beta-catenin signaling in vitro and in vivo. Proc Natl Acad Sci U S A (2007) 1.46
Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest (2005) 1.45
Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest (2007) 1.44
Value of novelty? Nat Rev Drug Discov (2002) 1.42
beta -Arrestin-mediated recruitment of the Src family kinase Yes mediates endothelin-1-stimulated glucose transport. J Biol Chem (2001) 1.35
Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis. Mol Pharmacol (2005) 1.33
Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act? Trends Pharmacol Sci (2007) 1.33
Imaging CXCR4 signaling with firefly luciferase complementation. Anal Chem (2008) 1.32
Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol (2007) 1.32
alpha-Thrombin induces rapid and sustained Akt phosphorylation by beta-arrestin1-dependent and -independent mechanisms, and only the sustained Akt phosphorylation is essential for G1 phase progression. J Biol Chem (2002) 1.30
beta-Adrenergic receptor kinase. Activity of partial agonists for stimulation of adenylate cyclase correlates with ability to promote receptor phosphorylation. J Biol Chem (1988) 1.28
Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Mol Pharmacol (1983) 1.22
Seven-transmembrane receptors. Nat Rev Mol Cell Biol (2002) 11.50
Beta-arrestins and cell signaling. Annu Rev Physiol (2007) 8.65
An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell (2005) 5.60
Seven-transmembrane-spanning receptors and heart function. Nature (2002) 5.38
The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci (2002) 5.04
beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem (2005) 4.91
Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci (2004) 4.44
Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci (2007) 4.35
Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A (2003) 3.99
A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A (2007) 3.82
Dishevelled 2 recruits beta-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. Science (2003) 3.52
Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science (2002) 3.46
GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab (2006) 3.34
Keeping G proteins at bay: a complex between G protein-coupled receptor kinase 2 and Gbetagamma. Science (2003) 3.27
Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol (2011) 3.15
Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest (2007) 3.15
New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell (2006) 3.11
Beta-arrestin-mediated localization of smoothened to the primary cilium. Science (2008) 3.10
Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci U S A (2007) 3.08
Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem (2004) 3.07
β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci (2011) 3.02
Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem (2006) 3.00
Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med (2010) 2.82
Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci U S A (2009) 2.76
A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell (2008) 2.76
Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol (2002) 2.76
Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell (2007) 2.65
Distinct phosphorylation sites on the β(2)-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin. Sci Signal (2011) 2.56
Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol (2003) 2.55
Trafficking of G protein-coupled receptors. Circ Res (2006) 2.54
Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. Proc Natl Acad Sci U S A (2005) 2.53
beta-arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem (2007) 2.51
Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci (2011) 2.51
Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc Natl Acad Sci U S A (2005) 2.48
The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem (2002) 2.47
beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci U S A (2003) 2.43
beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. J Biol Chem (2002) 2.42
beta2-adrenergic receptor signaling and desensitization elucidated by quantitative modeling of real time cAMP dynamics. J Biol Chem (2007) 2.42
Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J (2003) 2.42
Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. Proc Natl Acad Sci U S A (2003) 2.40
Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science (2003) 2.31
Defective lymphocyte chemotaxis in beta-arrestin2- and GRK6-deficient mice. Proc Natl Acad Sci U S A (2002) 2.26
Targeting of diacylglycerol degradation to M1 muscarinic receptors by beta-arrestins. Science (2007) 2.25
A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med (2009) 2.24
Multiple ligand-specific conformations of the β2-adrenergic receptor. Nat Chem Biol (2011) 2.23
Activity-dependent internalization of smoothened mediated by beta-arrestin 2 and GRK2. Science (2004) 2.19
Seven-transmembrane receptor signaling through beta-arrestin. Sci STKE (2005) 2.18
Overview of the Alliance for Cellular Signaling. Nature (2002) 2.15
Structure of active β-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. Nature (2013) 2.14
Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol (2011) 2.08
Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. Proc Natl Acad Sci U S A (2008) 2.06
Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron (2003) 2.03
Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci U S A (2006) 2.01
Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci (2002) 2.01
beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc Natl Acad Sci U S A (2004) 1.91
Trafficking patterns of beta-arrestin and G protein-coupled receptors determined by the kinetics of beta-arrestin deubiquitination. J Biol Chem (2003) 1.90
Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by beta-arrestins 1 and 2. J Biol Chem (2004) 1.86
Beta-arrestin-2 regulates the development of allergic asthma. J Clin Invest (2003) 1.85
Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci U S A (2009) 1.84
Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell (2009) 1.83
beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest (2009) 1.79
Beta-arrestin1 mediates insulin-like growth factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and anti-apoptosis. J Biol Chem (2003) 1.76
Activation-dependent conformational changes in {beta}-arrestin 2. J Biol Chem (2004) 1.76
Regulation of G protein-coupled receptor signaling by scaffold proteins. Circ Res (2002) 1.75
beta-Arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J Biol Chem (2004) 1.75
G-protein-coupled receptor kinase specificity for beta-arrestin recruitment to the beta2-adrenergic receptor revealed by fluorescence resonance energy transfer. J Biol Chem (2006) 1.73
beta -Arrestins regulate protease-activated receptor-1 desensitization but not internalization or Down-regulation. J Biol Chem (2001) 1.70
Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different pathways. J Biol Chem (2003) 1.66
Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL. Sci Signal (2009) 1.66
A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1. Nature (2011) 1.64
Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A (2010) 1.64
S-nitrosylation of beta-arrestin regulates beta-adrenergic receptor trafficking. Mol Cell (2008) 1.63
{beta}-Arrestin-2 Mediates Anti-apoptotic Signaling through Regulation of BAD Phosphorylation. J Biol Chem (2009) 1.59
Independent beta-arrestin2 and Gq/protein kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. J Biol Chem (2009) 1.57
Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol (2002) 1.55
Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation. Nature (2016) 1.55
Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science (2004) 1.52
Regulation of V2 vasopressin receptor degradation by agonist-promoted ubiquitination. J Biol Chem (2003) 1.50
Protein kinase A-mediated phosphorylation of the beta 2-adrenergic receptor regulates its coupling to Gs and Gi. Demonstration in a reconstituted system. J Biol Chem (2002) 1.50
Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci (2003) 1.49
Beta-arrestin-dependent signaling and trafficking of 7-transmembrane receptors is reciprocally regulated by the deubiquitinase USP33 and the E3 ligase Mdm2. Proc Natl Acad Sci U S A (2009) 1.49
Receptor-specific ubiquitination of beta-arrestin directs assembly and targeting of seven-transmembrane receptor signalosomes. J Biol Chem (2005) 1.47
Prolonged kappa opioid receptor phosphorylation mediated by G-protein receptor kinase underlies sustained analgesic tolerance. J Biol Chem (2003) 1.45
The use of lung donors older than 55 years: a review of the United Network of Organ Sharing database. J Heart Lung Transplant (2013) 1.42
Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2. J Biol Chem (2004) 1.41
The active conformation of beta-arrestin1: direct evidence for the phosphate sensor in the N-domain and conformational differences in the active states of beta-arrestins1 and -2. J Biol Chem (2007) 1.41
beta-Arrestin-dependent constitutive internalization of the human chemokine decoy receptor D6. J Biol Chem (2004) 1.39
Smoothened signal transduction is promoted by G protein-coupled receptor kinase 2. Mol Cell Biol (2006) 1.38
Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration. Circ Res (2008) 1.37
Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation. Circulation (2006) 1.37
Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J Biol Chem (2007) 1.36
Ubiquitination of beta-arrestin links seven-transmembrane receptor endocytosis and ERK activation. J Biol Chem (2007) 1.34
Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis. Mol Pharmacol (2005) 1.33
{beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J Biol Chem (2005) 1.31
Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. J Neurosci (2004) 1.26
Phosphorylation of beta-arrestin2 regulates its function in internalization of beta(2)-adrenergic receptors. Biochemistry (2002) 1.24
When 7 transmembrane receptors are not G protein-coupled receptors. J Clin Invest (2005) 1.24
Src-dependent tyrosine phosphorylation regulates dynamin self-assembly and ligand-induced endocytosis of the epidermal growth factor receptor. J Biol Chem (2002) 1.24
G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal. Br J Pharmacol (2003) 1.23